U.S. Markets closed

Relay Therapeutics, Inc. (RLAY)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
35.04-0.90 (-2.50%)
At close: 4:00PM EST
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close35.94
Bid34.98 x 800
Ask37.68 x 2200
Day's Range34.80 - 36.59
52 Week Range25.72 - 64.37
Avg. Volume859,188
Market Cap3.237B
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
Earnings DateAug 25, 2021 - Aug 30, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est54.33
  • Benzinga

    Notable Relay Therapeutics Insider Trades $890K In Company Stock

    Thomas Catinazzo, Insider at Relay Therapeutics (NASDAQ:RLAY), made a large buy and sell of company shares on November 15, according to a new SEC filing. What Happened: A Form 4 filing from the U.S. Securities and Exchange Commission states that Thomas Catinazzo exercised options to purchase 22,500 Relay Therapeutics shares at a price of $4.12 per share for a total of $92,700 on November 15. They then sold their shares on the same day in the open market. They sold at a price of $35.40 to raise a

  • Simply Wall St.

    How Many Relay Therapeutics, Inc. (NASDAQ:RLAY) Shares Do Institutions Own?

    If you want to know who really controls Relay Therapeutics, Inc. ( NASDAQ:RLAY ), then you'll have to look at the...

  • GlobeNewswire

    Relay Therapeutics Reports Third Quarter 2021 Financial Results and Recent Corporate Highlights

    CAMBRIDGE, Mass., Nov. 10, 2021 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, today reported third quarter 2021 financial results. “It’s been a very productive year at Relay Therapeutics. We have delivered on all of our key goals set out at our IPO in July 2020 and have proven our ability to effectively advance our clinical tria